一名携带EGFR外显子19 L747 - A750>P突变的肺腺癌患者对吉非替尼的原发性耐药。 - Suppr

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.

作者信息

Wei Qiang, Zhang Jin, Chen Dongsheng, Li Si, Liu Yuanhua

机构信息

Ultrasonic Department, Jiangsu Cancer Hospital &Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.

Intervention Department, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.

出版信息

Lung Cancer. 2020 Oct;148:175-176. doi: 10.1016/j.lungcan.2020.08.013. Epub 2020 Aug 21.

DOI:10.1016/j.lungcan.2020.08.013

PMID:32883519

Abstract

摘要

相似文献

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.一名携带EGFR外显子19 L747 - A750>P突变的肺腺癌患者对吉非替尼的原发性耐药。

Lung Cancer. 2020 Oct;148:175-176. doi: 10.1016/j.lungcan.2020.08.013. Epub 2020 Aug 21.

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.EGFR 突变型转移性非小细胞肺癌一线治疗中 exon19 缺失亚型的影响。

Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.表皮生长因子受体（EGFR）第20外显子插入突变的肺腺癌患者对阿法替尼单药治疗的主要临床反应

Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.一例表皮生长因子受体（EGFR）第19外显子新型倒位突变导致肺腺癌对EGFR酪氨酸激酶抑制剂原发性耐药的病例

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.肺腺癌中EGFR突变及其亚型的生物学特性与表皮生长因子受体酪氨酸激酶抑制剂疗效

Pathol Oncol Res. 2014 Apr;20(2):445-51. doi: 10.1007/s12253-013-9715-0. Epub 2013 Dec 3.

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.厄洛替尼对比吉非替尼用于治疗 EGFR 外显子 19 突变阳性的亚裔肺腺癌脑转移患者：一项回顾性、多中心研究。

BMC Pulm Med. 2018 Nov 20;18(1):171. doi: 10.1186/s12890-018-0734-1.

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.高剂量伏美替尼成功挽救治疗1例携带EGFR外显子20插入突变的肺腺癌患者

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.肺腺癌中 EGFR 外显子 19 突变 L747-A750>P 对酪氨酸激酶抑制剂表现出独特的敏感性。

Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10.

A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.具有新型表皮生长因子受体（EGFR）第20外显子插入突变的肺腺癌患者的一种可能的EGFR酪氨酸激酶抑制剂（TKIs）耐药机制：病例报告

Lung Cancer. 2021 Feb;152:193-195. doi: 10.1016/j.lungcan.2020.12.014. Epub 2020 Dec 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.

作者信息

机构信息

出版信息

相似文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献